Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Merck & Co.

Merck & Co.
1891 FOUNDED
PUBLIC STATUS
65K-70K EMPLOYEES
MRK STOCK SYMBOL
54 INVESTMENTS
$86.91 SHARE PRICE (As of Wednesday Closing)
Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the company's sales are generated in the United States.

Website
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NYS
Primary Office
  • 2000 Galloping Hill Road
  • Kenilworth, NJ 07033
  • United States

+1 (908) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Merck & Co.’s full profile, request a free trial.

Merck & Co. Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$66.10 - $87.25 $223B $85.65 $3.60 10.1M 2.57B

Merck & Co. Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 233,112,934 212,235,768 169,355,061 174,601,686
Revenue 44,367,000 42,294,000 40,122,000 39,807,000
EBITDA 16,051,000 13,649,000 11,566,000 10,495,000
Net Income 9,362,000 6,220,000 2,394,000 3,920,000
Total Assets 83,965,000 82,637,000 87,872,000 95,377,000
Total Debt 26,587,000 25,114,000 24,410,000 24,842,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Merck & Co. Competitors (69)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bristol-Myers Squibb Corporation New York, NY 00000 00000 000000000 00000
000 00000 Corporation Indianapolis, IN 00000 0000
0000000 Pending Transaction (PE) Summit, NJ 0000 000.00 000000&0 000.00
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
000000000000000 Corporation Brentford, United Kingdom 000000 00000000000
To view this company’s complete list of competitors, request access »

Merck & Co. Investments & Acquisitions (54)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 01-Jun-2019 000000000000000000 00000 Biotechnology 0000 00 00.0
0000000 0000000000 21-May-2019 000000000000000000 00.000 Pharmaceuticals 0000000 0000000 00
00000000 01-Apr-2019 000000000000000000 00.00 Electronic Equipment and Instruments 0000000 0000000 00
000000 000000 21-Feb-2019 000000000000000000 00000 Biotechnology 00000 0000000000 00.0
Alector 25-Jul-2018 Later Stage VC 00000 Drug Discovery
To view this company’s complete investment and acquisition history, request access »

Merck & Co. Exits (16)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 25-Jul-2018 00000 00000 00 00000 Completed
  • 20 buyers
0000000 07-Jan-2016 00000 00000 00 000.00 Completed
  • 12 buyers
0000000 00000000 06-Jan-2016 000000000 0000 Completed
  • 00000 & 00.
0000000 0000000000 09-Sep-2014 000000000000000000 Completed
  • 2 buyers
AdvanDx 08-Apr-2014 Later Stage VC 000.00 Completed
  • 4 buyers
To view this company’s complete exits history, request access »

Merck & Co. Subsidiaries (17)

Company Name Industry Location Founded
Tilos Therapeutics Biotechnology Lexington, MA 2016
00000000 Biotechnology Munich, Germany 0000
00000 000000 00000 Corporate Venture Capital Kenilworth, NJ 0000
00000 000000 Other Pharmaceuticals and Biotechnology Edinburgh, United Kingdom 0000
0000000000 Biotechnology Australia 0000
To view this company’s complete subsidiary history, request access »

Merck & Co. Executive Team (67)

Name Title Board
Seat
Contact
Info
Kenneth Frazier JD Chief Executive Officer & Chairman
Richard DeLuca Jr. Executive Vice President & President
Roger Perlmutter Ph.D Executive Vice President & President
Sanat Chattopadhyay Executive Vice President & President
Robert Davis JD Executive Vice President of Global Services and Chief Financial Officer

39 Former Executives

You’re viewing 5 of 67 executives. Get the full list »

Merck & Co. Board Members (20)

Name Representing Role Since Contact
Info
0000 000000 Self Board Member 000 0000
0000000 0000000 00 Merck & Co. Chief Executive Officer & Chairman 000 0000
000000 0000 Self Board Member 000 0000
0000 000 Merck & Co. Board Member 000 0000
000000 00000 Self Board Member 000 0000

7 Former Board Members

You’re viewing 5 of 20 board members. Get the full list »